Home LiteratureArticle Details
PMID: 59858 Published · ppublish English Journal Article

Small-cell carcinoma of the lung: attempt to remedy causes of past therapeutic failure.

Lancet (London, England) ·Vol. 2 ·No. 7980 ·1976-08-07 ·Pages 289-91

Johnson RE, Brereton HD, Kent CH

Abstract

A regimen of intensive, cyclic chemotherapy (cyclophosphamide, vincristine, doxorubicin administered concurrently with radiotherapy of bulk disease plus prophylactic whole-brain irradiation has been investigated for small-cell carcinoma of the lung. Treatment was completed in 12 weeks, after which patients were observed without maintenance therapy. Complete clinical remissions were noted in twenty of twenty-one patients with unresectable tumours, 10 of whom had distant extrathoracic spread upon admission. Survival has been prolonged and nine of the eleven patients with regional disease (mediastinal adenopathy with or without pleural effusion and/or supraclavicular nodes) have remained clinically disease-free for 6-14 months (median 10) and have resumed normal activities.

MeSH Terms
Adult Aged Carcinoma, Small Cell/drug therapy,radiotherapy,therapy Cyclophosphamide/therapeutic use Doxorubicin/therapeutic use Drug Therapy, Combination Evaluation Studies as Topic Female Humans Lung Neoplasms/drug therapy,radiotherapy,therapy Male Middle Aged Remission, Spontaneous Time Factors Vincristine/administration & dosage,therapeutic use
Chemicals
Vincristine Doxorubicin Cyclophosphamide
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Johnson R E
Brereton H D
Kent C H
Article Info
Journal
Lancet (London, England)
Abbr.
Lancet
ISSN
0140-6736
Published
1976-08-07
Pages
289-91
Language
English
Region
England
NLM ID
2985213R
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]